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Management strategies for acne vulgaris
Clinical question: What are the most effective treatment(s) for mild, moderate, severe, and 
hormonally driven acne?
Results: Mild acne responds favorably to topical treatments such as benzoyl peroxide, salicylic 
acid, and a low-dose retinoid. Moderate acne responds well to combination therapy comprising-
topical benzoyl peroxide, antibiotics, and/or retinoids, as well as oral antibiotics in refractory 
cases and oral contraceptive pills for female acne patients. Severe nodulocystic acne vulgaris 
responds best to oral isotretinoin therapy. In female patients with moderate to severe acne,  facial 
hair, loss of scalp hair and irregular periods, polycystic ovarian syndrome should be considered 
and appropriate treatment with hormonal modulation given. Adjunctive procedures can also be 
considered for all acne patients.
Implementation: Pitfalls to avoid when treating acne: treatment of acne in women of child-
bearing age; familiarization of all acne treatments in order to individualize management for   
patients; indications for specialist referral.
Keywords: acne vulgaris, benzoyl peroxide, retinoids, antibiotics, light and laser therapy, 
photodynamic therapy, photopneumatic therapy, chemical peels
Acne vulgaris
Definition: Acne vulgaris is a common multifactorial inflammatory condition of the 
pilo sebaceous follicle.
Classification: Based on the severity: mild, moderate, or severe, and the types of 
lesions present: comedones, papules, pustules, and nodules as well as the presence or 
absence of scarring.
Pathogenesis: Four factors: follicular epidermal hyper proliferation, surplus of sebum 
production, inflammation, and the concentration and activity of Propionibacterium 
acnes.1
Incidence: Mean age for the start of acne in girls is 11 years and boys 12 years, as 
concluded by several studies from multiple countries,2 with a peak at 15 to 18 years.3 
Acne prevalence in the adolescent community is estimated at 70% to 87%.2 In one   
large community based study in the United Kingdom, physiologic facial acne was seen 
in 54% of the adult population (ages 25 to 58 years), with clinical acne estimated at 
3% in adult men and 12% in adult women.4
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Assessment: Note areas involved (face, neck, chest, and/
or back), type and number of acne lesions, presence/absence 
and tendency for scarring, possible hormonal influence 
relating to acne flare, and the psychological role acne may 
be playing in the patient’s life.5 In females with moderate to 
severe acne, a history of facial hair, loss of scalp hair, and 
irregular periods should be noted. In males, use of anabolic 
steroids should be ascertained.
Outcomes: Patients seek improvement of acne lesions,   
with the hope of full clearing. Relapse is common. A patient 
specific course of therapy is needed, and may require trials 
of different medications and procedures until an optimal 
regimen is found.
Economics: US$100 million per year is spent on over-the-
counter treatments for acne, while the price of acne likely 
exceeds US$1 billion per year in the United States.6
Treatment: Goal of therapy is to target the four steps 
contributing to the pathogenicity of acne, while selecting 
a treatment based on the patient’s skin type and acne 
severity.
Consumer summary: Acne is a common skin complaint 
which can affect both genders at all ages. Treatment is 
based on the severity and appearance of acne, and consists 
of various topical and oral medications, as well as medical 
procedures.
The evidence
What treatments are most effective 
for mild to moderate acne?
Search sources: PubMed, Cochrane Library, Medline, clinical 
evidence.
Search strategy: Keywords used in this search include 
“mild acne”, “moderate acne”, “benzoyl peroxide”, “topical 
retinoids and acne”, “topical acne antibiotics”, and “oral 
acne antibiotics”. Articles used were limited to systematic 
reviews, meta-analyses, and randomized controlled trials 
(RCTs). Search limits include a publication date 1995 to 
present and English language. The systematic review and 
meta-analyses were selected based on evaluations of several 
current treatments for mild and moderate acne. RCTs were 
chosen based on investigator-blind or double-blind, random-
ized studies with at least an 11-week treatment duration, as 
well as documentation of acne severity, and reduction of total, 
inflammatory, and/or noninflammatory lesions. Two RCTs 
listed below (Thiboutot et al9 and Ozolins et al21) were also 
analyzed in the systematic review.
Systematic reviews:  1
Meta-analyses:  2
RCTs:   12 (Tables 1–3)
The systematic review7 looked at the efficacies and 
potential benefits of various topical and oral treatments for 
all stages of acne, and included 67 systematic reviews, RCTs, 
or observational studies. All medications were compared to 
placebo, except for oral erythromycin which was compared 
to oral doxycycline and oral tetracycline, as no placebo 
studies were found at the time of search. Results showed 
that benzoyl peroxide is effective as a first-line treatment 
for mild to moderate acne as measured by the reduction in 
total lesion counts. If acne does not significantly improve, 
tretinoin or adapalene are effective treatment options as both 
medications showed a reduction in noninflammatory and 
inflammatory lesion counts. Topical antibiotics (clindamycin 
and erythromycin) are an effective treatment for predominance 
of inflammatory lesions in mild to severe acne, and can be 
combined with a regimen that contains topical benzoyl perox-
ide, tretinoin, and/or adapalene. Evidence was lacking as to the 
success of oral antibiotics in treating acne, but is recommended 
for moderate acne patients whose acne severity has not been 
adequately reduced by the above topical treatments. Oral 
erythromycin demonstrated a similar efficacy to oral tetra-
cycline in total lesion count reduction. Oral doxycycline also 
showed a similar effectiveness as other oral antibiotics. One 
crossover RCT reported a statistically significant reduction 
(P = 0.001) in inflammatory lesions versus placebo after 
4 weeks with 100 mg daily of oral doxycycline.
The meta-analyses8 reviewed 23 studies of topical 
nonretinoid combination acne treatments in comparison to the 
corresponding single therapies in 7309 patients: 5% benzoyl 
peroxide + 2% salicyclic acid, 2.5% to 5% benzoyl per-
oxide + 1% to 1.2% clindamycin, 5% benzoyl peroxide, and 1% 
to 1.2% clindamycin. Acne severity was not specifically stated 
in the analysis results; however lesion counts were included and 
are most consistent in patients with moderate acne. In short, 
combination treatments offer the most favorable results in the 
reduction of acne lesions compared to the corresponding single 
therapies. Results showed that 5% benzoyl peroxide + salicylic Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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acid had the highest effectiveness in the reduction of lesions 
at 2 to 4 weeks compared to the other 3 treatments; however, 
benzoyl peroxide + clinamycin was equally as effective as 
benzoyl peroxide + salicyclic acid after 10 to 12 weeks. Mean 
percentage reduction in inflammatory lesion counts after 10 
to 12 weeks was: benzoyl peroxide + salicyclic acid = 51.8%, 
benzoyl peroxide + clindamycin = 55.6%, benzoyl perox-
ide = 43.7%, clindamycin = 45.9%, and placebo = 26.8%. 
Mean percentage reduction in noninflammatory lesions after 10 
to 12 weeks was: benzoyl peroxide + salicyclic acid = 47.8%, 
benzoyl peroxide + clindamycin = 40.3%, benzoyl perox-
ide = 30.9%, clindamycin = 32.6%, and placebo = 17%.
Conclusions
In the treatment of mild acne, benzoyl peroxide is an effec-
tive first-line treatment. If results are unsatisfactory, topical 
tretinoin or adapalene should be added.
In moderate acne, combination therapy has shown the most 
favorable results and typically consists of a regimen including 
benzoyl peroxide, topical antibiotics, and a topical retinoid 
(tretinoin, adapalene, or tazorotene). Tretinoin, adapalene, and 
tazorotene demonstrate similar effectiveness in the reduction of 
inflammatory, noninflammatory, and total lesion counts after 
12 weeks of treatment. Oral antibiotics may be tried for patients 
with a predominance of inflammatory lesions who have not 
responded favorably to the above topical treatments.
What treatments are most effective  
for severe acne?
Search sources: PubMed, Cochrane Library, Medline, clinical 
evidence.
Search strategy: Keywords used include “severe acne”, 
“cystic acne”, “conglobate acne”, “oral isotretinoin and 
acne”, and “systemic isotretinoin and acne”. Articles used 
were limited to systematic reviews, meta-analyses, and 
RCTs in the English language. No limits were placed on 
publication date. Systematic reviews were very limited 
and chosen based on evaluation of current treatments for 
severe acne. A meta-analysis was not found at the time of 
search. RCTs were also very limited and selected based 
on double-blind, randomized studies with documentation 
of acne severity.
Systematic reviews:  1
RCTs:  2 (Table 4)
The systematic review7 stated that oral isotretinoin is 
more effective than placebo and tetracycline at 1 month and 
24 weeks, respectively, in the reduction of lesions in severe 
acne patients. Only 1RCT (Peck et al22) was found in this 
systematic review comparing isotretinoin to placebo. Results 
of this study are listed in Table 4. When compared to tetracy-
cline at 24 weeks, isotretinoin significantly reduced acne cysts 
(P , 0.01), and pustules and comedones (P , 0.01).
Conclusions
In cases of severe acne, oral isotretinoin is the most 
effective therapy. In patients who are not candidates for oral 
isotretinoin, topical and oral treatments as mentioned above 
in treatments for mild to moderate acne can be considered 
in the treatment regimen.
Table 3 RCT of five antimicrobial treatment regimens for 18 weeks duration
Reference No of patients Acne 
severity
Treatment Treatment difference for 
patient’s perception of 
improvement, % (95% CI)
Odds ratio,  
(95% CI)
Ozolins 
et al21
oxytetracycline = 131 mild- 
moderate
500 mg oxytetracycline po  
bid (1) vs
2 vs 1 = −1.2 (−13.3–10.9) 0.95 (0.58–1.55)
minocycline = 130 100 mg minocycline  
po daily (2) vs
4 vs 1 = 11.1 (−0.7–22.9) 1.64 (0.98–2.74)
topical 5% BPO = 130 topical 5% BPO  
bid (3) vs
4 vs 2 = 12.3 (0.4–24.2) 1.74 (1.04–2.90)
topical 5% BPO + 3% 
erythromycin = 127
topical 5% BPO + 3%  
topical erythromycin
5 vs 4 = −3.5 (−15.2–8.2) 0.84 (0.50–1.42)
bid (4) vs 3 vs 1 = 5.0 (−7.0–17.0) 1.19 (0.72–1.96)
 
topical 2%
topical 2% erythromycin  
in AM + topical
3 vs 2 = 6.2 (−5.8–18.2) 1.26 (0.76–2.08)
erythromycin + 5% 
BPO = 131
5% BPO in PM (5) 3 vs 4 = −6.1 (−17.9–5.7) 0.72 (0.43–1.21)
Abbreviations: AM, morning; PM, evening; BPO, benzoyl peroxide; bid, twice daily; CI, Confidence interval; po, by mouth.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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What treatments are the most successful 
in reducing hormonally driven acne in 
women?
Search sources: PubMed, Cochrane Library, Medline, clinical 
evidence.
Search strategy: Keywords used include “acne and 
spironolactone”, and “oral contraceptives and acne”. Articles 
used were limited to systematic reviews, meta-analyses, 
and RCTs in the English language. No limits were placed 
on publication dates. A meta-analysis was not found and 
systematic reviews were limited to those presented below at 
the time of search. RCTs were limited and selected based on 
double blinding, randomization, and placebo control.
A: Spironolactone 
Systematic reviews:  1
RCTs:  1
The systematic review conducted by Brown et al24 
analyzed the role of spironolactone in hirsutism and/or acne. 
Most studies in this review examined only hirsutism as a 
treatment outcome, due to a lack of studies evaluating acne. 
The RCT by Muhlemann et al25 was included in this review 
and is summarized below. The authors concluded that there 
is “No evidence for effectiveness (of spironolactone) for the 
treatment of acne vulgaris. Studies in this area are scarce 
and small. Individual study data indicates some superiority 
of spironolactone over other drugs, but results cannot be 
generalized”.
A randomized double-blind trial conducted by Muhlemann 
et al,25 examined 200 mg daily of oral spironolactone for 
12 weeks versus placebo, and showed a statistically signifi-
cant improvement (P , 0.001) in spironolactone patients 
through the reduction of inflammatory lesions and patient 
perception of improvement. Photographs analyzed by 3 
blinded investigators during treatment also revealed an 
improvement (P , 0.02).
B: Oral contraceptive pills 
Systematic reviews:  1
RCTs:   6 (Table 5)
The systematic review conducted by Arowojolu et al26 
examined 25 trials of combined oral contraceptive pills (COCs) 
versus placebo and various hormone regimens in the treatment 
of female acne patients. In summary, “The four COCs evaluated 
in placebo-controlled trials are effective in reducing inflamma-
tory and noninflammatory facial acne lesions. Few important 
differences were found between COC types in their effective-
ness for treating acne”. Of these differences, COCs containing 
chlormadinone acetate or cyproterone acetate fair better than 
those containing levonorgestrel in reducing acne severity, but 
this observation is based on a small selection of data. Four stud-
ies listed in the review are also listed below in the RCTs.
Conclusion
In women with moderate to severe acne or acne refractory 
to treatment, placement on a combined oral contraceptive 
pill with or without spironolactone offers significant relief 
Table 4 rCTs of isotretinoin used to treat severe acne for 16 and 20 weeks respectively
Reference No of patients Acne  
severity
Treatment Reduction of 
inflammatory 
lesions, %
P value/CI Total reduction  
of lesions, %
P value/CI
Peck et al22 isotretinoin = 16  
vehicle = 17
severe isotretinoin vs 
placebo
n/a n/a After 8 wks  
32% decrease  
in cystic lesions  
in isotretoin  
group with  
placebo patients  
demonstrating  
a 57% increase  
in cystic lesions
P , 0.001 at   
1 month  
P , 0.008 at   
2 months  
between  
isotretinoin  
and placebo
Strauss et al23 Micronized 
isotretinoin = 300  
isotretinoin = 300
severe 0.4 mg/kg micronized 
isotretinoin per day  
without food vs  
1.0 mg/kg  
isotretinoin per day  
in 2 separate doses  
with food
87 
90
95%  
CI = 0.885–
0.989
89b 
 
90b
95%  
CIa = 0.899–
1.011
Notes: aequivalence between groups; btotal nodule counts.
Abbreviations: CI, confidence interval; n/a, data not reported.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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laser (1RCT) in the reduction of acne lesions. The authors 
conclude that the most dependable results from the above 
therapies are achieved with PDT through the reduction 
of inflammatory acne lesions. Limitations of this review 
include “suboptimal methodological quality” secondary to 
questionable randomization methods in 10 of the studies, 
but were included due to a limited selection. Several of the 
studies in this review are included in Table 6.
B: Photopneumatic therapy – IsolazTM
Search strategy: Keywords used include “acne and 
photopneumatic therapy”, “pneumatic energy”, “pneu-
matic therapy”, and “Isolaz”. There were no meta-analyses 
or systematic reviews at the time of search. Randomized 
controlled trials were limited to one unpublished study. No 
mention of randomization was found in the first two clinical 
trials listed below; these papers were obtained through inquiry 
to Solta Medical (Hayward, CA).
Clinical Trials:   2
RCTs:   1
Gold and Biron40 examined the efficacy of Isolaz™ 
(AestheraCorporation, Pleasanton, CA) a Food and Drug 
Administration (FDA) -approved treatment, in 11 mild to 
moderate acne patients with 4 total treatments at 3-week 
intervals. Three months after the fourth treatment, both inflam-
matory and noninflammatory lesions showed a statistically 
significant decrease (P = 0.0137, 0.0383, respectively) in 
number, but was based on 6 of the 11 patients.
Wanitphakdeedecha et al41 also examined photo-
pneumatic therapy in the treatment of 18 patients with 
mild–severe acne vulgaris. Patients received 4 treatments 
at 2-week intervals. An improvement of acne was demon-
strated after 2 treatments in most patients through clinical 
improvement scores and acne lesion counts. Severe acne 
patients received the greatest benefit in acne clearance 
from this treatment.
A recent unpublished study examining Isolaz + ada-
palene 0.3% versus adapalene 0.3% alone, showed a quicker 
improvement with the combination therapy, but after 4 weeks 
response to both treatments was similar.
C: Glycolic and salicylic acid chemical peels
Search strategy: Keywords used included “acne and chemi-
cal peels”. Papers were limited to meta-analyses, systematic 
reviews and RCTs in the English language. No meta-analysis 
or systematic review was found at the time of search. RCTs 
were extremely limited and were at least investigator-blind 
and randomized.
and reduction of acne lesions. More studies are needed 
to fully evaluate the potential benefit of spironolactone in 
improving acne.
nontraditional treatments  
in acne – are they effective?
Search sources: PubMed, Cochrane Library, Medline, clinical 
evidence.
We chose to focus on three popular areas of adjunctive 
treatments for mild–severe acne vulgaris: light, laser and 
photodynamic therapy (light therapy with a photosensitizer), 
photopneumatic therapy (light with vacuum therapy), and 
chemical peels.
A: Light, laser, and photodynamic therapy (PDT)
Search strategy: Keywords used included “acne and 
photodynamic therapy”, and “light and laser therapies and acne 
vulgaris”. Papers were limited to meta-analyses, systematic 
reviews, and RCTs in the English language. No meta-analysis 
was found at the time of search. RCTs were chosen based 
on controlled, randomized studies, and at least investigator-
blinding. All RCTs focused on facial acne, except for one study 
(Barolet and Boucher)35 involving back and facial acne.
Systematic reviews:   2
RCTs:   5 (Table 6)
Hamilton et al33 reviewed light therapy (13 trials) and PDT 
(12 trials) in the treatment of acne vulgaris. Acne severity 
in most trials was mild to moderate. Limits include a small 
sample size in many of the trials as well as questionable 
randomization and at least investigator-blinding methods. 
Light studies examined yellow, blue, red, and blue-red light 
as well as infrared radiation. In comparison to placebo, green 
and yellow light showed none to a minimal difference in acne 
improvement, and infrared radiation showed some improvement 
in comedones in one study and an improvement in mean lesion 
counts in another. The most favorable light therapy results 
were shown with red, blue, and blue-red light, demonstrating 
a statistically significant improvement (P , 0.05) in total or 
inflammatory lesion counts in 3 studies included in this review. 
PDT compared to light therapy showed a significant reduction 
in acne lesions favoring PDT in most studies.
The second systematic review34 of 16 RCT and 3 con-
trolled trials (CT) examined the efficacy of PDT (5 RCTs), 
infrared lasers (4 RCTs), broad-spectrum light sources 
(3 RCTs, 1CT), pulsed dye lasers (RCTs, 1CT), intense 
pulsed light (1 RCT, 2CT), and a potassium titanyl phosphate Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Table 6 rCTs for PDT with aminolevulinic acid therapy (ALA) and/or methyl aminolavulinate (MAL)
Reference No of  
patients
Treatment Outcome measures Results
Barolet and 
Boucher35
10 split face or back:  
pre-treatment with Ir LED  
(970 nm) + ALA + PDT LED  
(630 nm) vs ALA + PDT LED  
(630 nm)
reduction of  
inflammatory and  
noninflammatory  
lesions
73% reduction in Ir  
pre-treated side vs 38%  
reduction on control side  
after 4 weeks, P , 0.0001;  
also significant decrease in  
non-inflammatory lesions  
with Ir pre-treatment,  
P = 0.037
Wiegell and 
Wolf36
15 split face: ALA-PDT vs  
MAL-PDT
reduction of  
inflammatory and  
noninflammatory  
lesions
59% decrease in inflammatory   
lesions after 12 weeks  
with both treatments;  
no significant change in  
percent reduction of  
inflammatory lesions among  
the 2 treatments, P = 0.455;  
no significant difference  
in reduction of non- 
inflammatory lesions seen in  
both groups, P = 0.6355
Wiegell and 
Wolf37
21 full face: MAL + PDT vs  
control
reduction of  
inflammatory and  
noninflammatory 
lesions
68% reduction with  
MAL + PDT vs no difference  
in control after 12 weeks,  
P = 0.0023; no reduction in  
non-inflammatory lesions  
was seen
Horfelt et al38  30 split face: MAL + PDT vs  
placebo cream + PDT
reduction of  
inflammatory and  
non-inflammatory  
lesions
MAL + PDT resulted in  
54% median reduction of  
inflammatory lesions vs 20%  
with placebo cream + PDT  
after 12 weeks, P = 0.0006;  
no significant difference  
found in reduction of non- 
inflammatory lesions between   
the two groups; P = 0.6875  
for open comedones;  
P = 1.00 for closed  
comedones
Orringer et al39 44 split face: ALA + PDL vs  
control
reduction of  
inflammatory  
lesions
statistically significant  
decrease in inflammatory  
lesions in ALA + PDL group 
at 10 weeks (P = 0.01); effect  
was no longer seen at  
16 weeks
Abbreviations:  Ir, infared radiation; LED, light emitting diode; PDT, photodynamic therapy; PDL, pulsed-dye laser.
Ilknur et al43 also showed an equal effectiveness in 
the reduction of acne lesions with glycolic and amino 
fruit acid peels given every 2 weeks for 6 months in 
a split-face study with 24 patients. Noninflammatory 
lesions significantly decreased (P , 0.05) after 1 month 
with the glycolic acid peel and after 2 months with the 
amino fruit acid peel. Inflammatory lesions also decreased 
RCTs:   3
The RCT of Kessler et al42 examined the effectiveness of 
both a 30% glycolic acid peel and a 30% salicylic acid peel 
in 20 patients every 2 weeks for 6 treatments, with a split-
face application. Both peels showed a statistically significant 
decrease in acne lesions (P , 0.05) by the second treatment 
session, and proved equally effective.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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significantly (P , 0.05) after 5 and 6 months with the 
glycolic acid peel and after 5 months with the amino 
fruit acid peel.
In an unpublished study comparing 30% salicylic acid 
peels to IsolazTM, both treatments resulted in a similar 
improvement of acne lesions, with the Modified Global Acne 
Grading Scale demonstrating acne improvement before and 
after treatment of both procedures.
Conclusions
Blue and red light and PDT offer some relief in the reduction of 
inflammatory acne lesions, with the most promising results seen 
with PDT. The photosensitizers aminolevulinic acid and methyl 
aminolavulinate display similar effectiveness. Photopneumatic 
therapy (IsolazTM) and chemical peels also offer an improvement 
in acne lesions; however more studies are needed to fully assess 
the effectiveness of these medical treatments.
Table 7 Global Acne Grading System44
Location (L) Clinical assessment (A) Local score Global score
Forehead = 2 0 = no lesion Local score = L × A 0 = none
right cheek = 2 1 = $ 1 comedo sum of local scores = global score 1–18 = mild acne
Left cheek = 2 2 = $ 1 papule 19–30 = moderate acne
nose = 1 3 = $ 1 pustule 31–38 = severe acne
Chin = 1 4 = $ 1 nodule .39 = very severe acne
Chest/upper back = 3
The practice
Cautions
•  Women of child-bearing age and acne treatments:
    All topical acne therapy should be stopped if preg-
nancy occurs.
    Topical retinoids should not be prescribed to pregnant 
women, women wishing to become pregnant, or nurs-
ing patients.
    Oral tetracycline should not be taken by pregnant or 
nursing women.
    The only FDA-approved medication to treat 
acne during pregnancy is azelaic acid (category 
B) and should be used with caution in nursing   
women.
    It is imperative for women who are starting oral 
isotretinoin (category X) to practice 2 forms of birth 
control, participate monthly in pregnancy tests, and 
not become pregnant for at least 1 month after ces-
sation of therapy due to oral isotretinoin’s known 
teratagenic effects.
Management
•  Stress to patients that most acne therapies require at least 
8 to 12 weeks to see improvement.
•  Start with a medication with the most tolerable side effects 
and increase in strength as needed and tolerated by the 
patient.
•  Clinicians should match the patient’s skin type to 
formulation vehicle (dry skin type creams; oily skin type 
solutions/gels/salicylic acid products; normal skin type 
lotions).
Assessment
•  Thorough examination of face, neck, chest, and back.
•  Obtain detailed history of past acne medications.
•  Question males about anabolic steroid use and females 
about irregular periods, facial hair, and loss of scalp 
hair.
Treatment
•  Refer to Table 7 and Figures 1 and 2 for guidelines on 
acne treatment.
Specialist referral
•  Mild–severe acne patients.
•  Patient interest in nontraditional approaches to acne.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Nontraditional treatment options for acne vulgaris 
Chemical peels
Acne scarring
and/or mild-severe
acne pts with
sensitive skin type 
Glycolic acid peel
Mild-severe acne lesions
and/or oily skin type
Salicylic acid peel
Photopneumatic therapy-Isolaz™
Mild-severe acne
Light, laser and
photodynamic therapy 
Mild-severe acne; best for
predominance of inflammatory
acne lesions
Figure 2 Adjunctive acne treatment algorithm.
Comedonal lesions
Prescribe one of the following:
Topical retinoid
Benzoyl peroxide
Salicyclic acid
Azelaic acid 
If results are unsatisfactory,
increase strength or change
medication 
Mixed comedonal lesions and
papulopustules
Prescribe one of the following: 
Retinoid + topical antibiotic
Retinoid + benzoyl peroxide
Retinoid + benzoyl peroxide + topical 
antibiotic
Azelaic acid + benzoyl peroxide 
Azelaic acid + topical antibiotic
If results are unsatisfactory, prescribe
retinoid + course of oral antibiotic 
Cystic lesions 
Prescribe course of oral
antibiotic + mixed comedonal-
papulopustular topical therapy
If results are unsatisfactory,
consider whether patient is a
candidate for oral isotretinoin
therapy
If results are unsatisfactory,
consider possible endocrinopathy
If no sign of endocrinopathy is
found, consider repeat course of
oral isotretinoin If endocrinopathy is found, treat
Lesion types(s)
Figure 1 Guideline for acne treatment based on lesion type.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Further reading
Bolognia JL, Jorizzo J, Rapini R, et al. Dermatology. Section 6, pp. 531–45. 
London, Edinburgh, NY, Philadelphia, St Louis, Sydney, Toronto: 
Mosby; 2003.
Plewig G, KligmanAM. Acne and Rosacea. Berlin, Heidelberg: Springer; 
2000.
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